Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL therapy with chemotherapy with or without pembrolizumab in advanced NSCLC
NL-OMON53375Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of GC101 TIL + pembrolizumab, carboplatin, paclitaxel and pembrolizumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Leiden University Medical Center. Primary endpoint: Safety and toxicity. Started Dec 2023; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON53375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53375.